Genstruct: Patience, Persistence, and Payoff

Genstruct: Patience, Persistence, and Payoff

 
March 19, 2008

Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech. Most SB pioneers were founded as platform providers but soon encountered difficulties growing their sales sufficiently to increase valuations. Genstruct, a pioneer in using computational approaches to infer mechanistic hypotheses from large experimental data sets, is no exception.

Genstruct announces new collaboration with Pfizer in drug safety

 
CAMBRIDGE, Mass., February 20, 2008 /PRNewswire/ — Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology announced today that it has entered into a Master Research Agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.